ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangioc...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter V. Mazzaferro
Citation Annals of Oncology (2016) 27 (2): 102-117. 10.1093/annonc/mdw200
Authors V. Mazzaferro1, W. Shaib2, L. Rimassa3, W. Harris4, N. Personeni3, B. El-Rayes2, A. Tolcher5, T. Hall6, Y. Wang6, B. Schwartz7, J. Kazakin6, M. Droz Dit Busset8, C. Cotsoglou8, K. Papadopoulos5
  • 1Istituto Nazionale Tumori (National Cancer Institute), Milan, Italy, /
  • 2Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA, /
  • 3Humanitas Cancer Center, Istituto Clinico Humanitas IRCCS, Rozzano, Italy, /
  • 4University of Washington School of Medicine, Seattle, Washington, USA, /
  • 5South Texas Accelerated Research Therapeutics, San Antonio, Texas, USA, /
  • 6ArQule, Inc., Burlington, Massachusetts, USA, /
  • 7ArQule, Inc, Woburn, Massachusetts, USA, /
  • 8Instituto Nazionale Tumori, Milan, Italy, /


ARQ 087 is a potent, ATP competitive pan-FGFR inhibitor with additional activity against other kinases. FGFR signaling has been implicated in the development and progression of CCA, and FGFR2 fusion has been recognized as a therapeutic target in iCCA. ARQ 087 has been tested in over 80 cancer pts. Results of the Dose Escalation portion of this study were reported previously (Papadopoulos K et al. J Clin Oncol 33, 2015; suppl, abstr 2545).